Michelson et al 1 recently reported differences in platelet glycoprotein IIb/IIIa function in relation to the common Pl A1,A2 polymorphism. Pl A2 -positive platelets showed a lower threshold for activation. This was supported by the gene dosage effect: P1 A2 homozygotes had the highest activation of their platelets using a range of ADP concentrations.
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We are concerned about the conclusions regarding the antiplatelet effects of aspirin reached by the authors. At a low concentration of epinephrine (0.4 mol/L), there was no difference in platelet aggregation between the Pl A1,A1 and Pl A1,A2 genotypes, whereas increased aggregation was observed in the Pl A2,A2 group. Unexpectedly, the inhibitory effect of aspirin on epinephrine-induced (2.0 mol/L) platelet aggregation was found in the Pl A1,A2 group, but the opposite was found in Pl A2,A2 subjects. Two facts could explain this inconsistency. First, in experiments on the platelet aggregation response to aspirin, the number of Pl A1,A2 subjects included in the final analysis was diminished by 35%, because 7 of the 20 subjects did not achieve Ͼ60% aggregation at 10.0 mol/L epinephrine. Because platelet response to aspirin was calculated as a percent of aggregation determined in the absence of the inhibitor, the exclusion of "weak responders" could be the cause of a relevant bias. We wonder whether the results obtained could be attributed to an altered sensitivity to epinephrine, which was used in 3 different concentrations. Second, experiments performed in platelet suspensions do not necessarily reflect the wide array of platelet functional responses observed in vivo, particularly the reaction to vascular injury. The limitations of in vitro studies on platelet glycoprotein activation have been critically reviewed. 2 Platelets contribute to the explosive generation of thrombin by providing membrane surfaces for the assembly of the prothrombinase complex, which converts prothrombin to thrombin. In our study on the effects of aspirin on the formation of thrombin at the site of microvascular injury, 3 we found that P1 A2 carriers, most of them heterozygotes, had an impaired response to 75 mg of aspirin administered for 7 days. In fact, the odds for a failure of aspirin treatment in our study tripled in P1 A2 carriers. A recent report 4 on the increased risk of restenosis after coronary stent placement in P1 A2 carriers treated with aspirin and ticlopidine corroborates our observations. Moreover, these results are consistent with the finding that in patients treated with aspirin after coronary artery bypass surgery, the P1 A2 allele is a hereditary risk factor for bypass occlusion, myocardial infarction, and death. 5 Given the high frequency of the P1 A2 allele in the general population and growing evidence for lower clinical efficacy of aspirin treatment in P1 A2 carriers with atherosclerotic vascular disease, the results of the in vitro platelet aggregation experiments reported by Michelson et al 1 
Response
Szczeklik et al seem to agree with our conclusions about the prothrombotic phenotype of the platelet Pl A2 polymorphism, and we were pleased to see their own data, which was presented at the 1999 meeting of the International Society of Thrombosis and Haemostasis, showing shorter bleeding times in Pl A2 -positive subjects. They were concerned by the fact that our Pl A1,A2 study group was not intermediate to the other genotypes on aggregation with 0.4 mol/L epinephrine. This was almost certainly due to the relatively small numbers studied, because when Feng et al 1 assessed platelet hyperreactivity in 1422 subjects, they found a clear Pl A2 allele-dose response. The mechanism responsible for this Pl A2 -induced hyperreactivity seems to involve greater cell spreading, actin cytoskeleton reorganization, and postreceptor occupancy signaling. 2 Szczeklik et al thought that our finding that Pl A1,A2 platelets were more sensitive to the inhibitory effects of aspirin was inconsistent with their observation that Pl A1,A2 subjects were less sensitive to oral aspirin inhibition of thrombin generation. 3 We used turbidometric aggregation, the standard assay that has been used in countless patients to refine the efficacy of glycoprotein (GP) IIb/IIIa inhibitors. The assay used by Szczeklik et al measured prothrombin fragment (PF) 1.2 in blood from bleeding time-wounds. This latter assay has no clinical correlate and is not obviously related to GP IIb/IIIa function. Prothrombin competes with fibrinogen for activated GP IIb/IIIa but, unlike fibrinogen, prothrombin can to bind to GP IIb/IIIa on resting platelets. 4 Perhaps these PF 1.2 measurements reflect the mirror image of aggregation and our 2 sets of data are not inconsistent: if aspirin therapy causes greater platelet and GP IIb/IIIa inhibition in Pl A1,A2 platelets (our data), there would be less fibrinogen binding, which requires activated GP IIb/IIIa; this would permit greater prothrombin binding to resting GP IIb/IIIa, leading to more PF 1.2 production, which is consistent with the data of Szczeklik et al. In addition, their concerns that excluding "weak responders" to epinephrine might affect the results do not seem logical: if we had a greater proportion of "strong responders" in the Pl A1,A2 group, one would expect less (not more) inhibition by aspirin.
Finally, Szczeklik et al refer to 2 reports that found Pl A2 was a risk factor for poor outcomes after coronary revascularization procedures, despite treatment with aspirin. However, to say that there was an increased risk in Pl A2 patients treated with aspirin seems erroneous because it is a conclusion about data that was not presented in the article by Kastrati et al, 5 who found that female sex was the only characteristic that interacted with Pl A2 . Furthermore, because virtually none of the 40ϩ studies on Pl A2 risk specifically tested for an aspirin interaction, despite its common use in cases and controls, this issue cannot be addressed from the available literature. Unfortunately, a perfect opportunity to address the question of an interaction between aspirin and Pl A2 was missed by the Physician Health Study when they did not analyze their patients who had myocardial infarction separately from patients who had venous thrombosis over the period of time when patients were randomized to receive aspirin or placebo. 6 Szczeklik et al conclude by saying our data should be interpreted with caution. We agree and would like to quote our
